VivoSeq
Other

PD-1 Inhibitors

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

PD-1 Inhibitors is an early-stage landscape with 0 programs across 2 companies. The most active players are Silverback Therapeutics, AskGene Pharma, Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Silverback Therapeutics

0 programs

PreclinicalA

AskGene Pharma, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Unknown status4 · 36%
Completed4 · 36%
Not yet recruiting1 · 9%
Recruiting1 · 9%
Active, not recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

PD-1 Inhibitors Maintenance for cHL Post-autoHCT
Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06812858·83 enrolled
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
Active, not recruiting·AAskGene Pharma, Inc.·Phase 1/2·NCT05632939·62 enrolled
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Not yet recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1/2·NCT07133776·30 enrolled
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Completed·PPeking University·Phase 2·NCT05166239·66 enrolled
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
Completed·TThe First Hospital of Hebei Medical University·N/A·NCT07053215·60 enrolled
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Completed·HHunan Cancer Hospital·N/A·NCT06031376·106 enrolled
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
Completed·FFirst Hospital of China Medical University·N/A·NCT06631326·244 enrolled
Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05549336·100 enrolled
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Unknown status·SSilverback Therapeutics·Phase 1·NCT04460456·58 enrolled
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC
Unknown status·—·N/A·NCT04063449·170 enrolled
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
Unknown status·JJiangsu Cancer Institute & Hospital·Phase 1·NCT06045286·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)